Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.52 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | ABL2 | P42684 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | HCK | P08631 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22315064 | 0.84 | KIT (0.47) | MAP4K4KIT | |
| SCHEMBL15043242 | 0.83 | KIT (0.46) | MAP4K4KIT | |
| SCHEMBL27120776 | 0.79 | MAP4K4 (0.52) | MAP4K4KIT | |
| SCHEMBL15023106 | 0.79 | KIT (0.43) | MAP4K4KITFGFR1 | |
| SCHEMBL15023696 | 0.76 | KIT (0.41) | MAP4K4KITEGFRFGFR1 | |
| SCHEMBL15046128 | 0.74 | KIT (0.46) | MAP4K4KIT | |
| SCHEMBL275263 | 0.73 | MAP4K4 (0.47) | MAP4K4KITEGFRFGFR1KDR | |
| SCHEMBL19698007 | 0.73 | MAP4K4 (0.47) | MAP4K4KITEGFRCDK1KDR | |
| SCHEMBL13075093 | 0.73 | MAP4K4 (0.47) | MAP4K4KIT | |
| SCHEMBL15023176 | 0.72 | KIT (0.44) | MAP4K4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| WO-2020156982-A1 | THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-06 | — | — | WO | disclosed |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| US-9598416-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598416-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598416-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-2791140-B1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-06-15 | — | — | EP | disclosed |
| EP-2791140-B1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-06-15 | — | — | EP | disclosed |
| EP-2465505-A1 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Bayer HealthCare LLC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133995-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | BAYER HEALTHCARE LLV (US) | 2009-11-12 | — | — | US | disclosed |
| EP-1957077-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer HealthCare LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064883-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, FGFR1, FGFR3 | MAP4K4 1344/4885KIT 2169/4885ACVRL1 543/4885 |
| US-20090281079-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis | CDK4, FLT4, CDKL4 | MAP4K4 127/4885KIT 2199/4885ACVRL1 1003/4885 |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | FGFR1, NR5A2, FGFR3 | MAP4K4 1328/4885KIT 2141/4885ACVRL1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.